Orphazyme postpones 2021 annual report

Beleaguered biotech company Orphazyme will publicize its full-year financial figures on April 7 instead of the previously announced date, March 15.

Anders Vadsholt, CEO of Orphazyme | Photo: Orphazyme / PR

Onlookers and shareholders who want to get their hands on the annual report from biotech firm Orphazyme, which has been besieged by bad news in recent times, will have to wait a little longer.

Orphazyme has changed the publishing date, pushing back the report by almost a month from the previously announced March 15 to April 7, according to a company press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs